arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

NewcelX Ltd.

NCEL
$3.56 ▲ +0.12 (+3.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
9 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NewcelX Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.7M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -27.9%
FCF / Share $-0.72
Trailing P/E 1.7x
Price / Book 2.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 5, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-8.30M
↓ -15.3%
FCF / Share Free cash flow per share
$-0.72
↓ -99.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Financial Health
12
Cash Quality
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 9 quarters